Argenica Therapeutics Ltd · ASX:AGN
Argenica Therapeutics — Shareholder Meeting (November 2024)
27 slides from Argenica Therapeutics's shareholder meeting presentation, Nov 13, 2024
Slide 1: AGM Chair's Address & Managing Director Presentation
ASX ANNOUNCEMENT AGM CHAIR’S ADDRESS & MANAGING DIRECTOR PRESENTATION Perth, Australia; 13 November 2024 - Argenica Therapeutics Limited (ASX: AGN) (“Argenica” or the “Company”), is pleased to provide below copies of the Chair’s Address and Managing Director Presentation given at its Annual General
Slide 2: Chair's Address (continued)
HIE and others creates value in our assets for prospective partnering and enhances the underlying company valuation. To enable this growth strategy requires the right human capital with the requisite skills and experience. In this regard, we are delighted to welcome Mr Rob Black with his strong fina
Slide 3: Chair's Address close and About Argenica
I thank my fellow directors, both past and current for their commitment to Argenica from its early days as a spin out entity, to a listed company and in the support of its mission as a neurology clinical development company. I would like to note that Liddy McCall is not seeking re-election at this m
Slide 4: Argenica Therapeutics Managing Director Presentation November 2024
ARGENICA THERAPEUTICS AGM PRESENTATION ASX: AGN MANAGING DIRECTOR PRESENTATION NOVEMBER 2024 1 www.argenica.com.au
Slide 5: Disclaimer
DISCLAIMER This presentation has been prepared by Argenica Therapeutics Limited and its related entities (the “Company”) and is not an offer document. It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company
Slide 6: The Therapeutic Opportunity
NEUROPROTECTION ARGENICA THERAPEUTICS THE THERAPEUTIC OPPORTUNITY 3 www.argenica.com.au
Slide 7: Breakthrough Neuroprotective Therapy
BREAKTHROUGH NEUROPROTECTIVE THERAPY ABOUT ARG-007 MISSION Commercialise a neuroprotective treatment that minimises brain damage and fosters recovery Cationic poly-arginine peptide following stroke & other neurological conditions Multiple mechanisms of action ARGENICA THERAPEUTICS working across mul
Slide 8: We Had a Very Successful 2024
WE HAD A VERY SUCCESSFUL 2024 COMMENCEMENT OF PHASE 2 CLINICAL TRIAL IN ACUTE ISCHAEMIC STROKE (AIS) PATIENTS DOSED 63% OF PATIENTS IN PHASE 2 IN AIS ARGENICA THERAPEUTICS NO SERIOUS ADVERSE EVENTS RELATED TO DRUG ADMINISTRATION IN FIRST 50% PATIENTS DOSED POSITIVE IND ENABLING STUDIES FOR STROKE SI
Slide 9: Our Lead Drug Candidate ARG-007
OUR LEAD DRUG CANDIDATE ARG-007 DISCOVERY PRE-CLINICAL PHASE 1 PHASE 2 PHASE 3 Efficacy Safety / Tox STROKE Damage to the brain from interruption of its blood supply SEVERE TBI ARGENICA THERAPEUTICS Trauma to the head or body causes a loss of consciousness HIE Hypoxic ischemic encephalopathy (HIE) d
Slide 10: Potential of ARG-007
POTENTIAL OF ARG-007 MAIN INDICATIONS ADDRESSABLE MARKET SUMMARY OF RESULTS TO DATE STROKE USD$12bn 66% reduction 70% reduction by 20301 in Brain Tissue Death 24 hours after stroke in Brain Tissue Death 28 Days after stroke 1. Coherent Market Insights Report – Acute Ischemic Stroke (AIS) Market Anal
Slide 11: Key Company Metrics
KEY COMPANY METRICS $13.9M $93.5M +$4M CASH @ BANK 1 MARKET CAP2 NON-DILUTIVE GRANTS 3 ARGENICA THERAPEUTICS 128.1M 37% SHARES HELD BY TOP 20 63% SHARES ON ISSUE PATIENTS ENROLLED IN PHASE 24 1. Cash balance as @ 30 September 2024 2. Calculated with closing price on @25th October 2024 being $0.75 8
Slide 12: Phase 2 Stroke Trial
PHASE 2 ARGENICA THERAPEUTICS STROKE TRIAL 9 www.argenica.com.au
Slide 13: So Why Are We Targeting Stroke First?
SO WHY ARE WE TARGETING STROKE FIRST? INCIDENCE SOCIETAL IMPLICATIONS THE IMPORTANCE OF TIME ARGENICA THERAPEUTICS 45 SECONDS ONLY 10% 1.9 MILLION How often someone will recover almost brain cells are attacked each suffers an ischaemic completely, due to the extent minute during a stroke3 stroke in
Slide 14: Encouraging Stroke Results to Date
ENCOURAGING STROKE RESULTS TO DATE SUCCESSFUL PHASE 28 Days 1 (HUMAN after stroke in STUDY) PRECLINICAL & CLINICAL DATA preclinical model4 100% INDUCED Reduction in brain 90% STROKE cell death can make a significant difference SAFE TO 80% to patients’ outcome. ADMINISTER It could mean the IN THE FIE
Slide 15: Phase 2 Stroke Trial
ARGENICA THERAPEUTICS PHASE 2 STROKE TRIAL 12 www.argenica.com.au
Slide 16: Phase 2 Trial Design in Acute Ischaemic Stroke
PHASE 2 TRIAL DESIGN IN ACUTE ISCHAEMIC STROKE PATIENT HAS A PATIENT IN ARRIVES AT DIAGNOSE REHAB STROKE AMBULANCE HOSPITAL STROKE TYPE THROMBECTOMY BEGINS ARGENICA THERAPEUTICS Initial screening of Administration of Endpoints patients to meet inclusion 0.3mg/kg ARG-007 or Mortality rate and frequen
Slide 17: Example of What Phase 2 Trial Hopes to Achieve
EXAMPLE OF WHAT PHASE 2 TRIAL HOPES TO ACHIEVE: PROTECTING VULNERABLE BRAIN TISSUE (PENUMBRA) FOLLOWING STROKE & THROMBECTOMY Infarct core: permanent brain cell death Penumbra: Surrounding tissue ARGENICA THERAPEUTICS that is still alive but vulnerable ARG-007 aims to protect the vulnerable penumbra
Slide 18: Phase 2 Clinical Trial in Stroke
PHASE 2 CLINICAL TRIAL IN STROKE 10 Australian hospitals activated to recruit 92 ACTUAL PATIENT RECRUITMENT patients, currently 63% patients dosed1. 100 Double-blinded, randomised, placebo- 90 controlled study with 0.3mg/kg dose of ARG- 007. ARGENICA THERAPEUTICS 80 70 ARG-007 given to patients that
Slide 19: Phase 2 Enrolment
PHASE 2 ENROLMENT 92 participants being enrolled across 10 stroke centres in Australia: ARGENICA THERAPEUTICS 16 www.argenica.com.au
Slide 20: The Opportunity for ARG-007 in Other Indications
THE OPPORTUNITY ARGENICA THERAPEUTICS FOR ARG-007 IN OTHER INDICATIONS 17 www.argenica.com.au
Slide 21: ARG-007 Potential in TBI – Rat Data
ARG-007 POTENTIAL IN TBI – RAT DATA ARG-007 SIGNIFICANTLY REDUCES NFH PROTEIN AND APP FOLLOWING TBI2 TRAUMATIC 2000 180 BRAIN 1800 160 51% 52% INJURY 1600 reduction reduction 140 1400 ARGENICA THERAPEUTICS 120 Density of NFH (mm2) Density of APP (mm2) 1200 100 1000 Estimated USD$18.6bn 80 market siz
Slide 22: ARG-007 Potential in TBI – Ferret Data
ARG-007 POTENTIAL IN TBI – FERRET DATA ARG-007 SIGNIFICANTLY REDUCES AMYLOID PRECURSOR PROTEIN (APP) AND NEUROFILAMENT M-14.9 (RMO-14) & FOLLOWING TBI1 70% 51% 75% 64% reduction reduction ARGENICA THERAPEUTICS ARG-007 was found to protect brain cells in the injured brain by significantly reducing th
Slide 23: ARG-007 Potential in HIE
ARG-007 POTENTIAL IN HIE TOTAL BRAIN INJURY AT 4 WEEK POST HIE WITH ARG-007 TREATMENT OR ARG-007 WITH STANDARD OF CARE HYPOTHERMIA3 HYPOXIC-ISCHAEMIC ENCEPHALOPATHY (HIE) ARGENICA THERAPEUTICS HIE occurs in 1.5 to 2.5 births per 10001 Current standard of care is hypothermia Awarded A$2.5m grant to a
Slide 24: FDA Has Granted ODD & RPDD Status for HIE
FDA HAS GRANTED ODD & RPDD STATUS FOR HIE1 Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation status to ARG-007 and ARG- 006 for the treatment of Hypoxic Ischaemic Encephalopathy (HIE). ARGENICA THERAPEUTICS ODD qualifies AGN for incen
Slide 25: 2025 Will Be Equally Exciting
2025 WILL BE EQUALLY EXCITING… Our core areas of focus will be: ARGENICA THERAPEUTICS Submission of Investigational New Drug Application to the FDA Completion of patient dosing in Phase 2 clinical trial Topline data on the safety and preliminary efficacy of ARG-007 in acute ischaemic stroke patients
Slide 26: Argenica Board
ARGENICA BOARD ARGENICA THERAPEUTICS Dianne Angus Dr Liz Dallimore Robert Black Dr Mark Etherton Terry Budge Non-Executive Chairman Managing Director Non-Executive Director Non-Executive Director Non-Executive Director • Senior executive within the • Over 20 years' experience in • 30 years’ experien
Slide 27: For Further Information Please Contact
ARGENICA THERAPEUTICS For further information please contact: Dr Liz Dallimore CEO & Managing Director E: info@argenica.com.au 24 www.argenica.com.au
Argenica Therapeutics — Shareholder Meeting (November 2024) on 6ix